S
Susan L. Uprichard
Researcher at Loyola University Medical Center
Publications - 80
Citations - 5245
Susan L. Uprichard is an academic researcher from Loyola University Medical Center. The author has contributed to research in topics: Hepatitis C virus & Virus. The author has an hindex of 26, co-authored 75 publications receiving 4940 citations. Previous affiliations of Susan L. Uprichard include Loyola University Chicago & Shaare Zedek Medical Center.
Papers
More filters
Journal ArticleDOI
Robust hepatitis C virus infection in vitro
Jin Zhong,Pablo Gastaminza,Guofeng Cheng,Sharookh B. Kapadia,Takanobu Kato,Dennis R. Burton,Stefan Wieland,Susan L. Uprichard,Takaji Wakita,Francis V. Chisari +9 more
TL;DR: A simple yet robust HCV cell culture infection system based on the HCV JFH-1 molecular clone and Huh-7-derived cell lines that allows the production of virus that can be efficiently propagated in tissue culture is reported.
Journal ArticleDOI
Identification of the Niemann-Pick C1–like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor
Bruno Sainz,Naina Barretto,Danyelle N. Martin,Nobuhiko Hiraga,Michio Imamura,Snawar Hussain,Katherine A. Marsh,Xuemei Yu,Kazuaki Chayama,Waddah A. Alrefai,Susan L. Uprichard +10 more
TL;DR: It is shown that the cellular Niemann-Pick C1–like 1 (NPC1L1) cholesterol uptake receptor is an HCV entry factor amendable to therapeutic intervention and discovered a new antiviral target and potential therapeutic agent.
Journal ArticleDOI
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
Jeremie Guedj,Harel Dahari,Harel Dahari,Harel Dahari,Libin Rong,Natasha Sansone,Natasha Sansone,Richard E. Nettles,Scott J. Cotler,Thomas J. Layden,Susan L. Uprichard,Susan L. Uprichard,Alan S. Perelson +12 more
TL;DR: It is shown that understanding the effects of daclatasvir in vivo requires a multiscale model that incorporates drug effects on the HCV intracellular lifecycle, and this approach is validated with in vitro HCV infection experiments and yields a more precise estimate of the serum HCV half-life.
Journal ArticleDOI
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
Christopher Koh,Laetitia Canini,Laetitia Canini,Harel Dahari,Harel Dahari,Xiongce Zhao,Susan L. Uprichard,V. Haynes-Williams,Mark A. Winters,Gitanjali Subramanya,Stewart Cooper,Peter A. Pinto,Erin F. Wolff,Rachel Bishop,Ma Ai Thanda Han,Scott J. Cotler,David E. Kleiner,Onur Keskin,Ramazan Idilman,Cihan Yurdaydin,Jeffrey S. Glenn,Theo Heller +21 more
TL;DR: Treatment of chronic HDV with lonafarnib significantly reduces virus levels and the decline in virus levels significantly correlated with serum drug levels, providing further evidence for the efficacy of prenylation inhibition in chronicHDV.
Journal ArticleDOI
Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs.
TL;DR: It is demonstrated that efficiently delivered siRNAs should be able to silence HBV in chronically infected patients.